Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

  • ID: 4240144
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • ADC Therapeutics
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Ferring
  • LIDDS
  • Nymox Pharmaceutical
  • MORE

About Benign Prostatic Hyperplasia Drugs

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

The analysts forecast the global benign prostatic hyperplasia drugs market to grow at a CAGR of 7.07% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global benign prostatic hyperplasia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Benign Prostatic Hyperplasia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Astellas Pharma
- Eli Lilly
- GlaxoSmithKline
- Sanofi

Other prominent vendors
- ADC Therapeutics
- Advaxis
- Agennix
- ANI Pharmaceuticals
- Bayer HealthCare
- BHR Pharma
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Dendreon (Valeant Pharmaceuticals)
- Eisai
- Endo Pharmaceuticals
- Ferring
- Foresee Pharmaceuticals
- Io Therapeutics
- LIDDS
- Madrigal Pharmaceuticals
- Merck
- Novartis
- Nymox Pharmaceutical
- Spectrum Pharmaceuticals
- Takeda Pharmaceuticals
- Teva Pharmaceutical Industries
- Urologix

Market drivers
- Growing geriatric male population.
- For a full, detailed list, view the full report

Market challenges
- Availability of minimally invasive surgery as a drug replacement.
- For a full, detailed list, view the full report

Market trends
- Advancements in early-stage diagnosis through new diagnostic methods.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ADC Therapeutics
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Ferring
  • LIDDS
  • Nymox Pharmaceutical
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: BPH diagnostics
  • Overview
PART 06: Pipeline landscape

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by MOA
  • Alpha-blockers
  • 5-ARIs
  • PDE-5 inhibitors
  • Others
PART 09: Geographical segmentation
  • BPH drugs market in Americas
  • BPH drugs market in EMEA
  • BPH drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Advancements in early-stage diagnosis through new diagnostic methods
  • Growing demand for MRI and ultrasound-guided prostate biopsy procedures
  • Growing focus toward new MOA
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Risk factors of prostate gland enlargement
Exhibit 02: Difference between prostate cancer and BPH
Exhibit 03: Pipeline analysis
Exhibit 04: Pipeline landscape
Exhibit 05: Global BPH drugs market snapshot
Exhibit 06: Global BPH drugs market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by MOA 2016
Exhibit 09: Global BPH alpha-blockers drugs market 2016-2021 ($ millions)
Exhibit 10: Global BPH 5-ARIs drugs market 2016-2021 ($ millions)
Exhibit 11: Global BPH PDE-5 inhibitors drugs market 2016-2021 ($ millions)
Exhibit 12: Segmentation of global BPH drugs market based on geography 2016 and 2021 (%)
Exhibit 13: Global BPH drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: BPH drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: BPH drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: BPH drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Percentage of potential population for BPH among people with 65+ years 2014 and 2050
Exhibit 21: Prominent side effects of BPH medication
Exhibit 22: Impact of patent loss on AVODART 2014-2015 (GBP millions)
Exhibit 23: New advancements in diagnosis of BPH
Exhibit 24: Competitive structure analysis of global BPH drugs market 2016
Exhibit 25: Competitive analysis of global BPH drugs market
Exhibit 26: Astellas Pharma: Strength assessment
Exhibit 27: Astellas Pharma: Strategy assessment
Exhibit 28: Astellas Pharma: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Sanofi: Key highlights
Exhibit 37: Sanofi: Strength assessment
Exhibit 38: Sanofi: Strategy assessment
Exhibit 39: Sanofi: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ADC Therapeutics
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Ferring
  • LIDDS
  • Nymox Pharmaceutical
  • MORE
New Report Released: – Global Benign Prostatic Hyperplasia Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global benign prostatic hyperplasia drugs market: Astellas Pharma, Eli Lilly, GlaxoSmithKline, and Sanofi.

Other Prominent Vendors in the market are: ADC Therapeutics, Advaxis, Agennix, ANI Pharmaceuticals, Bayer HealthCare, BHR Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Dendreo (Valeant Pharmaceuticals), Eisai, Endo Pharmaceuticals, Ferring, Foresee Pharmaceuticals, Io Therapeutics, LIDDS, Madrigal Pharmaceuticals, Merck, Novartis, Nymox Pharmaceutical, Spectrum Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, and Urologix.

Commenting on the report, an analyst from the research team said: “One trend in market is advancements in early-stage diagnosis through new diagnostic methods. New diagnostic methods for BPH are likely to boost the diagnosed patient pool, thereby fueling the market growth. The market has seen the emergence of novel diagnostic tests, which are expected to be more accurate than the conventional PSA blood test. Considering the failure of PSA test to detect early-stage BPH, researchers have been working on new diagnostic methods to improve diagnosis.”

According to the report, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. However, the chances of developing this disorder among the population of under 40 years are rare. This indicates that rising aging male population is directly proportional to the risk of BPH. Currently, out of the total older population in the world, those aged above 65 years are the fastest-growing population group, accounting for 8.1% of the total population in 2014. This group is expected to reach 16% by 2050. This scenario is expected to drive the market growth.

Further, the report states that one challenges in market is availability of minimally invasive surgery as a drug replacement. The growing popularity of minimally invasive surgeries as an alternative to the drug to cure BPH could hinder the market growth. The minimally invasive alternatives such as laser surgeries, transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), and open or laparoscopic subtotal prostatectomy require less recovery time with a minimum hospital stay. Since the maximum number of individuals are diagnosed at the chronic stages, the physicians prefer surgeries, which helps treat the indication effectively. Further, laparoscopic surgeries and robotic surgeries are gaining traction in the market, as they offer individuals a quicker and comfortable recovery option. In addition, transurethral resection of the prostate (TURP) is one of the most common treatment approaches for enlarged prostate in which resectoscope equipped with small cutting tools is inserted into the urethra to remove blocking cells, thereby relieving the individual from BPH symptoms.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi
  • ADC Therapeutics
  • Advaxis
  • Agennix
  • ANI Pharmaceuticals
  • Bayer HealthCare
  • BHR Pharma
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Dendreo (Valeant Pharmaceuticals)
  • Eisai
  • Endo Pharmaceuticals
  • Ferring
  • Foresee Pharmaceuticals
  • Io Therapeutics
  • LIDDS
  • Madrigal Pharmaceuticals
  • Merck
  • Novartis
  • Nymox Pharmaceutical
  • Spectrum Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Urologix
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll